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Abstract 
 
Introduction. Financial toxicity (FT) is a well-recognized problem in oncology. US-based studies 
have shown that: (a) cancer patients have a 2.7 times risk of bankruptcy; (b) patients who declare 
bankruptcy have a 79% greater hazard of death; (c) financial burden significantly impairs quality of 
life (QoL), and (d) reduces compliance and adherence to treatment prescriptions. The aim of the 
project is to develop and validate a patient-reported-outcome (PRO) measure to assess FT of 
cancer patients in Italy, where, despite the universal health coverage given by the national health 
service, FT is an emerging issue. 
Methods and analysis. Our hypothesis is that a specific FT measure, which considers the relevant 
socio-cultural context and health care system, would allow to understand the main determinants 
of cancer-related financial toxicity in Italy and to contrast them. According to the International 
Society for Pharmaco-economics and Outcomes Research (ISPOR) guidelines on PROs, the  project 
will include the following  steps: (1) concept elicitation (from focus groups with patients and 
caregivers; literature; oncologists; nurses) and analysis, creating a coding library; (2) item 
generation (using a format that includes a question and a response on a 4-point Likert scale) and 
analysis through patients’ cognitive interviews of item importance within different coding 
categories to produce the draft instrument; (3) factor analysis and internal validation (with 
Cronbach’s alpha and test-retest for reliability) to produce the final instrument; (4) external 
validation with QoL anchors and depression scales. The use of the FT measure in prospective trials 
is also planned.  
Ethics and dissemination. The protocol is approved by the ethical committees of all the 
participating centres. The project will tentatively produce a validated tool by the spring 2021.The 
project might also represent a model and the basis for future cooperation with other European 
countries, with different health care systems and socio-economic conditions.  
 
ARTICLE SUMMARY 
Strengths and limitations of this study 
• Previous research data support that financial problems do affect the outcome of cancer 
patients in Italy, and despite the Italian health care system is grounded on universal 
coverage, financial constraints may greatly impact in the future on cancer patient access to 
health care goods and services in the future. 
• The way health care and welfare systems are shaped does impact on financial toxicity 
suffered by cancer patients and instruments for its description need to be developed 
locally. 
• This protocol applies a widely accepted methodology for the production of patient 
reported outcome measures.  
• The rational of this protocol is that an instrument measuring cancer-related financial 
toxicity may be conducive to corrective policies that might ultimately benefit patients 
• For the same reasons that make appropriate the development of a local instrument more 
than the application of an already existing tool developed elsewhere, one intrinsic 
limitation is that, being developed in Italy, our instrument will be applicable to Italian 
patients only.  
INTRODUCTION 
Financial problems are a matter of global attention in oncology, focusing on two levels of financial 
difficulties: third payer and individual patient. Payers are generally affected the rising cost of 
anticancer drugs.1 2 At the patient level, in the United States (US), co-payment is becoming 
unaffordable and, as a consequence, cancer patients have higher likelihood to file for bankruptcy 
than the general population.3 In addition, financial difficulties have been associated with lower 
patient satisfaction,4 worse compliance,5 worse quality of life (QoL),6-8 and worse survival.9 
Particularly, Ramsey and collaborators have shown that US cancer patients who declared 
bankruptcy have a hazard ratio of death of 1.79 (95% CI 1.64-1.96) as compared with a population 
of cancer patients who did not file for bankruptcy and were matched in a propensity score analysis.9 
The problem is being reported in other countries and with varied types of health care systems. 10-13 
 
The need for specific tools to address this problem has been acknowledged in the scientific 
community, and in the US a patient-reported-outcome (PRO) instrument, called “COST”, has been 
recently proposed for measuring financial distress.14 COST is a questionnaire composed of 11 
items addressing psychologic response to financial problems and coping behaviours. This 
questionnaire does not address material conditions that cause financial problems, and is highly 
specific for US context, where cancer diagnosis translates into an excess of out-of-pocket 
expenses.15 COST has been validated in some clinical settings, e.g. in a series of 100 multiple 
myeloma patients after at least 3 months of medical treatment, in a series of 233 patients 
undergoing chemotherapy for solid tumors, and in a series of 191 Japanese patients receiving 
chemotherapy for a solid tumor for at least 2 months.. 16-18 However, this questionnaire might not be 
appropriate and sensitive to relevant issues in health systems where co-payment for anticancer 
drugs is not required.  
 
In Italy, we have recently shown that financial difficulties exist and negatively affect the outcomes 
of cancer patients undergoing anticancer treatment, in terms of both QoL and life expectancy. 19 We 
used the EORTC QLQ-C30 questionnaire in several clinical trials of treatment of solid tumours, 
promoted by the National Cancer Institute of Napoli during the last two decades. Therefore, taking 
advantage of the existing databases, we performed a pooled analysis of 16 trials including 3670 
patients, with the aims of exploring the relevance of financial difficulties in the Italian public health 
care system. We analysed question 28 of the EORTC QLQ-C30asking: 'During the last week, has 
your physical condition or medical treatment caused you financial difficulties?', where financial 
difficulties related to disease or treatment are measured in four categories, from 'not at all' to 'very 
much'.20 We defined financial burden (FB) as any financial difficulty reported at baseline 
questionnaire, and financial toxicity (FT) as score worsening in a subsequent questionnaire. We 
investigated (i) the prognostic role of FB on clinical outcomes (survival, global QoL response 
[items 29/30] and severe toxicity), and (ii) the effect of FT on survival. For the latter analysis, a 
landmark time of 4.5 months was applied, excluding all the patients dead or censored before the 
landmark, because they had no or fewer chances to suffer FT, and their inclusion in the analysis 
would have biased toward a worse prognosis the group of patients without FT. Analyses were 
performed using logistic regression models or the Cox model adjusting for trial, gender, age, region 
and period of enrolment, baseline global QoL and, where appropriate, FB and global QoL response. 
At baseline, 26% of the 3670 study patients reported FB. Such FB was not associated with 
increased risks of death (HR 0.94, 95%CI: 0.85-1.04, p=0.23) or increased risk of severe toxicity 
(OR 0.90, 95%CI: 0.76-1.06, p=0.19) but was predictive of a higher chance of worse global QoL 
response (OR 1.35, 95%CI: 1.08-1.70, p=0.009). During treatment, 2735 patients filled in 
subsequent questionnaires; out of them, 616 (22.5%) developed FT. FT was associated with a 
statistically significant higher risk of death (HR 1.20; 95% CI: 1.05-1.37, p=0.007), when the 
landmark time of 4.5 months was used. Results did not vary in sensitivity analyses when landmark 
threshold was increased and trials or disease or setting of treatment were removed one at a time.  
 The hypothesis underlying this project is that a specific instrument might help to describe and 
understand determinants and effects of cancer-related FT in Italy and that some of these may be 
modified, ultimately improving prognosis of cancer patients.  
Therefore, the aim is to develop and validate a PRO instrument to describe and measure FT of 
Italian patients on cancer treatment, hereby described as “patient reported outcome for Fighting 
Financial Toxicity of cancer” (proFFiT).  
The impact of this project might be relevant for patients’ prognosis if we were able to understand 
how to intervene on FT, through adequate policies, because the size of the prognostic impact that 
we described in our preliminary study is similar to the magnitude of the benefit produced by several 
new drugs approved and reimbursed in Italy during the last few years.19 Therefore, the negative 
effect of FT, when occurring, may ultimately lessen the positive impact of some anticancer drugs; 
but, on the contrary, effective strategies contrasting FT, might synergize with anticancer treatment 
and produce relevant benefit for cancer patients without increasing side-effects.  
 
METHODS AND ANALYSIS 
The project will be conducted according to the methodology delineated by the International Society 
for Pharmaco-economics and Outcome Research (ISPOR) Patient Reported Outcomes Content 
Validity Good Research Practices Task Force.21 22 
The project includes 5 tasks, summarised in table 1. 
 
Task 1: concept elicitation and coding 
Specific aim 
To elicit concepts and coding them into a thematic library. 
 
Context of use 
Our preliminary data were obtained in a context of Medical Oncology units in public general 
hospitals, University Oncology units and public Cancer Institutes in Italy, where patients with 
specific types of solid tumours (lung, breast or ovarian cancer), mostly at an advanced stage of 
disease, underwent medical treatment, prevalently first-line therapy. In this project, the context will 
be expanded in order to include patients with any type of solid cancer or haematological 
malignancy who are undergoing or have recently completed medical treatment, including 
chemotherapy, target agents, immunotherapy, hormonal treatment, radiotherapy and combinations 
of such therapies.  
 
Inclusion and exclusion criteria 
The following are the major inclusion/exclusion criteria of the patients who will be involved in the 
project, also representing the target population for the use of the instrument in future studies. 
 
Inclusion Criteria  
- Adult patients (>18 years) 
- Histologically or citologically confirmed diagnosis of any type of solid cancer or 
haematological malignancy  
- Written informed consent provided 
- Medical treatment (chemotherapy, target agents, immunotherapy, hormonal treatment, 
radiotherapy or combinations of such therapies) ongoing or terminated within the previous 3 
months.  
- Caregivers of patients who meet the above criteria 
 
Exclusion Criteria  
- Patients with major cognitive dysfunction or psychiatric disorders 
- Patients who have never received anticancer medical or radiation treatment 
 
Sources for concept elicitation 
Four different sources of information will be used for concept elicitation.  
 
Literature review 
A literature review will be conducted including international and Italian documents including 
scientific documents found through PubMed, CINAHL and EMBASE by cross checking references, 
and publicly available documents not cited in PubMed but found through patients’ advocacy 
websites, government agencies and common web research engines. Content will be divided in 
single items that will be subsequently categorized according to the conceptual framework.  
 
Focus groups 
Focus groups will be carried out in three towns, distributed in North, Central and South Italy. In 
order to reach a point of saturation, two focus groups will be organized in each town: one with 
patients receiving or having recently received medical anticancer treatment, and one with caregivers 
of patients receiving or who have recently received anticancer treatment. A maximum of 10 
individuals will be included, led by a skilled moderator with the help of an assistant moderator. 23 
All focus groups will be audio-recorded and transcribed verbatim. Content analysis will be 
conducted with a qualitative software (T-Lab). Qualitative analysis of focus group outcomes will be 
done using the constant comparison technique guided by the Grounded Theory approach.24 25 
 
Expert opinions 
Expert opinions will be sought through the cooperation with Associazione Italiana di Oncologia 
Medica (AIOM), Collegio Italiano dei Primari di Oncologia Medica Ospedalieri (CIPOMO), 
Federation of Italian Cooperative Oncology Groups (FICOG), Associazione Italiana Infermieri di 
Area Oncologica (AIIAO), using web or email surveys.  
 
Interviews 
Two types of interviews will be conducted.  Patients and caregivers presenting at the info-points of 
Italian Association of Cancer Patients (AIMAC) in Italian hospitals in Northern, Central and 
Southern Italy will be invited to respond to question 28 of the EORTC QLQ-C30 questionnaire 
after a brief identification of baseline socio-cultural characteristics. Those who reveal some degree 
of economic problem at question 28 (score ≥2), will be invited to participate in a brief semi-
structured interview to describe individual experiences of financial difficulties during cancer 
treatment. Sample size will be determined based on findings during ongoing qualitative analysis, in 
order to guarantee saturation.    
Qualitative interviews of consenting patients and caregivers will be conducted by nurses in 3 
participating centres representing Southern (Naples), Central (Rome) and Northern (Turin) Italy, 
with the aim of exploring the lived experience of financial difficulties that occur during cancer 
treatment. The sample size will be defined by the principle of saturation (in order to guarantee the 
presence of patients and caregivers who have experienced the phenomenon, and to have 
demographic variability by region, sex, gender and age, when possible). It is estimated that 8-10 
patients and caregivers from each centre will be adequate. Subjects participating in the interviews 
will have signed informed consent, be at least 18 years of age, have had experience of financial 
difficulty as a patient who has received cancer treatment, or as caregiver who has experienced 
financial difficulty while caring for a family member receiving treatment for cancer. Subjects with 
cognitive impairments or any physical or medical reason (i.e. excessive fatigue) that would not 
permit participation in an interview will be excluded.  Patients will be interviewed individually, and 
in private. Interviews will be audio recorded and later transcribed verbatim.   
 
Coding and interpretation 
Concepts collected through the analysis of the different sources will be coded in an iterative process 
with opportunities for data to be re-examined and reanalyzed until no new codes or code groupings 
are identified and all passages from the transcripts have been assigned one or more codes.  
Redundancy and overlapping content will be controlled. Content comparison analysis will be also 
associated with the analysis of a qualitative software (e.g. T-Lab), and concepts will be divided into 
different themes.   
Data interpretation will flow upward from content comparison analysis, coding procedure results 
and data outputs from qualitative software. A quasi-statistics approach will be used to attain simple 
descriptive counts of categories, levels of consensus/dissent and about response patterns among the 
focus group members or the professionals responding to surveys and interviewees. 23.  
 
Products and timelines of Task 1 
A list of concepts organized in a thematic coding library will be the product of task 1 activities, 
within 6 months from the beginning of the project. The protocol will be published to encourage 
debate and prompt cooperation with other European countries.  
 
Task 2: Item generation and analysis 
Specific aim 
To generate a draft version of the instrument.  
 
Criteria for item generation 
Major criteria informing item generation are based on the prevalent characteristics of PRO 
instruments already available in Italian language and widely used in oncology (e.g. EORTC 
questionnaires).  Major criteria include: 
- Item structure using a question/response model (rather than statement/agreement) 
- Short questions 
- Simple language (avoiding technical words) 
- No jargon. 
 
Recall period 
No single recall period is definitely best for all measures or all phenomena.26 In the context of 
PROs, the recall period must correspond to the characteristics of the phenomenon of interest and the 
purpose of the assessment. Similar to the COST instrument, a 7-day recall period will be initially 
used.  
 
Wording of items and responses 
The formulation of each new item will respect the wording and the language suggested during the 
concept elicitation phase in order to maintain a high level of fidelity and transparency. 27 The 
response scheme will follow a 4-point Likert scale (not at all/a little/quite a bit/very much). 
Alternative formats will be explored, if needed.  
Items will be reviewed separately by the members of the Steering Committee and a consensus will 
be sought for each of them, also checking for redundancy, overlapping content and ambiguous 
language. 
 
Item importance analysis 
Item importance will be ranked by a sample of 45 patients (15 for each centre, Naples, Rome and 
Turin, selected with the same inclusion/exclusion criteria reported above). Patients will be asked to 
score importance of items within each theme by using a 4-point Likert scale (not important at all / a 
little important / quite a bit important / extremely important). Within each theme, at least three items 
with the highest rank will be retained for subsequent steps. 
 
Cognitive interviews 
The list of items remaining after importance analysis, will be administered to a separate sample of 
45 patients (15 for each centre, Naples, Rome and Turin, selected with the same inclusion/exclusion 
criteria reported above) followed by cognitive interviews conducted by trained psychologists. 28 The 
number of patients is based on a convenience sampling inspired by a grounded theory 
framework.25According to this framework, frequencies are rarely important, as one occurrence of 
the data is potentially as  useful as many in understanding the process behind a topic. Therefore, 
sample size should generally follow the concept of saturation, a point when the collection of new 
data does not shed any further light on the issue under investigation.  
Within such semi-structured interviews, items will be evaluated for comprehensibility, recall, 
judgment and response, mapping a standardized feedback evaluation. Also, the structure and format 
of the instrument will be evaluated for readability, clarity of presentation, ease of administration.  
Consideration will be given to potential changes in mode of administration, as this study will 
evaluate the administration via tablet or smart phone. In this phase, criteria to retain, modify or 
reject items will be also based on missing values, item difficulty, discriminatory ability, 
comprehensibility and relevance. 
 
Products and timelines of Task 2 
A draft instrument will be the product of task 2 and should be available by month 15. A paper 
focusing on the qualitative research outcomes of the first phases of the project is planned.  
 
Task 3:  Instrument refinement and internal validation 
Specific aim 
To generate the final version of the proFFiT instrument.  
 
Definition of scoring procedures 
A global score deriving from the rough sum of the response scores at each item might be calculated, 
representing a continuous numeric measure of FT. This will be discussed within the Steering 
Committee, in order to take into account the information contained in retained items. It is expected 
that single-item questions will be produced to check for possible determinants of FT. 
 
Factor analysis 
To refine the instrument from the draft to the final version, a principal components analysis 
(explorative factor analysis) will be undertaken with data from the first field test (eigenvalue limit 
will be set at 1). Structural equation models could also be used to take into account causal variables. 
 
Reliability 
Internal reliability of multi-item scales will be assessed by analysing inter-item correlations and 
Cronbach's α coefficient adjusted by the number of items. Estimates of α >0.70 will be considered 
acceptable, confidence intervals will be provided by bootstrap methods. 
To assess the test-retest reliability, the intraclass correlation coefficient (ICC) will be estimated 
repeating the questionnaire administration within a week from the first use. With one-sided alpha 
0.05, 80% power, a minimally acceptable level of reliability equal to 0.70 and an expected ICC of 
0.80, 118 patients are needed (10-12 for each centre, in 10-12 oncologic centres distributed in north, 
Central and South Italy, selected with the same inclusion/exclusion criteria reported above).29 
 
Products and timelines of Task 3 
The final instrument will be the product of task 3 and should be available by month 24. A paper 
presenting the final instrument is planned. 
 
Task 4: External validation 
Specific aim 
To generate data on external validity of the final proFFiT instrument.  
 
External validation 
Criterion validity will be performed using different anchors. First, the correlation of proFFiT with 
response to question 28 of the EORTC QLQ-C30 questionnaire will be assessed. Second, based on 
the assumption that a high degree of financial problems correlates with worse quality of life, the 
correlation with the global health-related quality of life EORTC score (questions 29-30) will be 
assessed. A similar analysis done with the COST score showed a Pearson correlation coefficient of 
0.26. 16 We plan to test correlations with bilateral alpha 0.05, 80% power and expected Pearson 
correlation coefficient of 0.20. For this analysis, 194 patients are required and around 220 patients 
will be enrolled to allow for some missing data. Descriptively, correlation of proFFiT with the 
Hospital Anxiety and Depression Scale (HADS) will be studied as well. For this analysis, patients 
beginning a therapeutic cycle, already experienced with medical or radiation treatment of cancer, 
will be enrolled.  
 
Responsiveness 
To test responsiveness (to which extent the instrument is sensitive in capturing the changes of the 
variable of interest within-patients) repeated measures (at each cycle or every 3-4 weeks) of 
proFFiT will be collected together with the EORTC QLQ-C30. Changes over time will be 
estimated. Further correlation of proFFiT with response to question 28 will be evaluated. 
Responsiveness will be longitudinally tested with the same sample of patients planned for criterion 
validity. 
 
Products and timelines of Task 4 
Description of correlation of the final instrument with external anchors will be the product of task 4 
and should be available by month 36. A paper will be submitted reporting the external validation 
data. 
 
Task 5: Application in clinical studies 
Specific aim 
Use of proFFiT in subsequent prospective patient series is the aim of task 5. This task is reported 
here for completeness. Specific protocols will be developed and will undergo proper approval once 
Tasks 1 to 4 have been completed. 
 
Endpoint models 
proFFiT may be used in at least three different endpoint models, depicted in the figure 1. 
 
Clinical study within the endpoint model 1 
A large scale multi-centre cross-sectional observational study will be performed, where proFFiT 
will be used to describe financial toxicity across a patient population defined according to type or 
stage of disease, or any other selection criteria.  
The study will include patients with any type of solid tumours or hematologic malignancy. 
Specific aims will be: 
• to describe prevalence of financial toxicity in general and according to different 
subcategories (geographical, personal, socio-economical, cancer-related, treatment-related); 
• to describe the behaviour of proFFiT within repeated measures over the time in patients 
undergoing medical treatment for cancer; 
• to describe variability of psychometric properties of proFFiT over the time;  
• to describe the correlation between proFFiT and typical endpoint of cancer treatments (e.g. 
compliance, QoL, survival).  
The study will include at least 1000 patients and efforts will be done to include relevant categories 
in terms of gender, age, geographic location, type of cancer, performance status and type of 
treatment (classes of drugs, radiotherapy). During this phase, the cooperation of major cooperative 
Italian groups (represented by the Federation of Italian Cooperative Oncology Groups - FICOG) 
will be of primary importance because it will guarantee feasibility with many participating centres.  
 Clinical study within the endpoint model 2 
In the end-point model 2, studies might be proposed based on the content of proFFiT instrument. 
According to the content of the items that will be retained in the final instrument, we might face 
with different material conditions that may be cause of financial distress. All the efforts will be 
done to understand how such conditions can be experimentally modified and prospective pilot 
studies will be planned to produce preliminary evidence on the possible efficacy of corrective 
actions. The number and the type of these trials will depend on the type of material conditions listed 
in the proFFiT.  
 
Clinical study within the endpoint model 3 
In the endpoint model 3, the planned use of the instrument is more traditional, being one of the 
elements that should be analysed as secondary endpoint in trials testing the efficacy of new drugs or 
treatment strategies. In principle, in this model, consideration should always be given to the context 
of development of the instrument and therefore this model would apply to the Italian context only. 
Such studies might be implemented within this project, either based on the findings of the previous 
phases or planned by other independent investigators, once proFFiT has been made available to the 
Italian scientific community. 
 
Data collection procedures 
The Unità Sperimentazioni Cliniche at Istituto Nazionale per lo Studio e la Cura dei Tumori 
Fondazione G. Pascale IRCCS manages a website (www.usc-intnapoli.net) hub platform for the 
conduction of multicentre clinical trials, including facilities for patients registration, randomization, 
data collection through electronic case report forms, data management through an e-query system, 
and collection of radiological examination for independent review. Recently, the collection of 
patient-reported-outcome questionnaires from mobile devices has been implemented and will be 
used in this project. All web-site activities are fully tracked and verifiable and the whole system is 
under a quality assurance program. The site is accessible by username and password, and is 
protected through encrypted data certified by SSL and HTTPS protocols. From 2007 to 2015, 
180.000 web accesses have produced 216.000 electronic case report forms. Data are managed by an 
in-house server, with regular backup, redundant features and onsite maintenance.  
Therefore, patient registration and data collection will be centralized and web-based.  Interviews, 
audio-visual data management will be analysed and transferred for storage by a dedicated software. 
 
Patient and Public Involvement   
The Steering committee of the protocol includes four representatives (FDL, LDC, EI, FT) of Italian 
and European patients’ associations (FAVO, AIMAC, ECPC) who meet regularly with all the other 
members and share all the decisions assumed by the committee. Therefore, they partnered for the 
design of the study, some of the activities performed in the concept elicitation phase, and in all the 
steps where the Steering Committee will assume decisions regarding the project. They will also be 
involved in dissemination and proposition of future studies using the proFFiT instrument. 
 
 
Project status 
March 2018: Start of tasks including patients (focus groups) 
October 2019: planned time for submission of a paper reporting on qualitative tasks  
March 2020: planned time for final instrument availability  
March 2021: planned time for submission of a paper reporting on the final validated instrument 
(end of task 4). 
 
Ethics and dissemination 
The present research is a non-profit investigator study. The promoter (National Cancer Institute of 
Naples) will stipulate an agreement with participating centres. Study protocol, patient information 
and informed consent have been approved by the coordinating Ethical Committee on November 
2017. 
At each centre, the study will only be started after being approved by the institutional Ethical 
Committee. Furthermore, Ethical committees will be informed of any planned changes of study 
protocol.  
The study has been registered on clinicaltrials.gov with the code NCT03473379. 
Publications arising from study data will be determined by the Study Steering Committee. 
All the Authors reported in the front page will be actively involved in manuscript preparation. All 
study publications will report the statement “… on behalf of the proFFiT Investigators”.  
Table 1. Summary table of planned tasks 
 
 Task 1 Task 2 Task 3 Task 4 Task 5 
Title Concept elicitation and 
coding 
Item generation and 
analysis 
Instrument 
refinement and 
internal validation 
External validation 
 
Application in clinical 
studies 
Aim To elicit concepts and 
coding them into a 
thematic library. 
To generate a draft version 
of the instrument.  
To generate the final 
version of the 
instrument. 
To generate data on 
external validity of the 
final instrument. 
Use in prospective 
clinical studies. 
Actions Literature review. 
Focus groups with 
patients and caregivers. 
Opinion of oncologists 
and nurses, through 
scientific societies. 
Info points AIMAC 
(patients and 
caregivers). 
Wording of items.  
Importance analysis with 
patients (15 patients per 
geographic region). 
Item analysis with cognitive 
interviews of patients (15 
patients per geographic 
region). 
Factor analysis. 
Reliability analysis 
(Cronbach alpha, test-
retest with 118 
patients). 
Communication of 
results. 
Correlation with 
anchors (EORTC QLQ-
C30 – namely Q28 and 
Q29&30; HADS) and 
responsiveness; with 
patients. 
Communication of 
results. 
Promote and perform 
a large scale 
multicentre cross-
sectional clinical trial. 
Communication of 
results. 
Psychologists 
involved 
Yes, for focus group and 
coding activities. 
Yes, for cognitive interviews 
and analysis. 
No No No 
Patients involved 30 divided in 3 focus 
groups and 
approximately 25 for 
qualitative interviews. 
90 (45 for importance 
analysis and 45 for cognitive 
interviews). 
118 based on sample 
size estimation. 
220 based on sample 
size estimation. 
1000 based on gross 
estimation. 
Products Thematic library of 
concepts. 
Paper reporting the 
protocol.  
Pre-final instrument. 
Paper reporting on 
qualitative research 
outcomes of the project. 
Final instrument. 
Paper presenting the 
final instrument. 
Correlation with 
external anchors. 
Paper reporting on 
validation. 
Knowledge on 
prevalence and risk 
factors for FT in Italy.  
At least one paper 
describing results of 
the cross-sectional 
study. 
Duration  6 months  9 months  9 months  12 months  24 months  
 
Legend of figure 
Figure 1. Endpoint models for future use of proFFiT  
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